# TherapeuticsMD, Inc.: Form 10-K for the period ended Dec 31, 2013

- Company: [TherapeuticsMD, Inc.](/companies/txmd.md) (CIK 25743)
- Form: 10-K
- Filed: 2014-03-05
- Accepted by EDGAR: Mar 5, 2014, 17:10 ET
- Period: 2013-12-31
- Accession: 0001387131-14-000771
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/25743/000138713114000771/txmd-10k_123113.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/25743/000138713114000771/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-10-01 to 2013-12-31 | $2.9m | us-gaap:SalesRevenueNet |
| Revenue | 12 months, 2013-01-01 to 2013-12-31 | $8.8m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months, 2013-01-01 to 2013-12-31 | $2.0m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2013-10-01 to 2013-12-31 | $2.4m | us-gaap:GrossProfit |
| Gross profit | 12 months, 2013-01-01 to 2013-12-31 | $6.8m | us-gaap:GrossProfit |
| Research and development | 12 months, 2013-01-01 to 2013-12-31 | $13.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2013-01-01 to 2013-12-31 | $19.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2013-01-01 to 2013-12-31 | −$25.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2013-01-01 to 2013-12-31 | $1.2m | us-gaap:InterestExpense |
| Net income | 3 months, 2013-10-01 to 2013-12-31 | −$8.4m | us-gaap:NetIncomeLoss |
| Net income | 12 months, 2013-01-01 to 2013-12-31 | −$28.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-10-01 to 2013-12-31 | −$0.06 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months, 2013-01-01 to 2013-12-31 | −$0.22 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2013-01-01 to 2013-12-31 | −$20.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2013-01-01 to 2013-12-31 | $40.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-12-31 | $54.2m | us-gaap:Cash |
| Current assets | at 2013-12-31 | $59.4m | us-gaap:AssetsCurrent |
| Total assets | at 2013-12-31 | $62.0m | us-gaap:Assets |
| Current liabilities | at 2013-12-31 | $7.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-12-31 | $7.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-12-31 | $54.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/25743/000138713114000771/txmd-10k_123113.htm

Filed Mar 5, 2014.
Source: SEC EDGAR, the filing index for accession 0001387131-14-000771. Last ingested by Listed: Nov 14, 2026, 19:24 ET. No prices; not investment advice.
